04 June 2019
Visiongain has published a new pharma report Global Antifungal Drugs Market Forecast 2019-2029: Azoles, Echinocandins, Polyenes, Allylamines, Voriconazole, Posaconazole, Clotrimazole, Isavuconazole, Fluconazole, Caspofungin, Micagunfin, Amphotericin, Lamisil, Dermatophytosis, Aspergillosis, Candidiasis.
The global antifungal drugs market is estimated to have reached $14bn in 2018 and is expected to grow at a CAGR of 3.8% during the forecast period. In 2018, the global antifungal drugs market was dominated by Azoles.
This report profiled the selected companies: Abbott Laboratories, Bayer AG, Enzon Pharmaceuticals, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Kramer Laboratories, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Sanofi S.A. and others.
The lead analyst commented that "Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.
The antifungal drugs market is mainly driven by the incidence and prevalence rate of antifungal infections. Moreover, cost-effective products, growing population of immunocompromised individuals and minimal side-effects are other factors that will drive market growth. However, antifungal drugs market has some restraints such as the presence of alternative therapies."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
10 August 2020
Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.
06 August 2020
Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.
05 August 2020
With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.